mepolizumab


( Last Updated : May 13, 2022)
Generic Name:
mepolizumab
Project Status:
Received
Therapeutic Area:
Severe chronic rhinosinusitis with nasal polyps
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Nucala
Project Line:
Reimbursement Review
Project Number:
SR0735-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Add on to standard of care for adult patients (18+) with severe nasal polyps inadequately controlled by intranasal corticosteroids (INCS) alone defined as: - Documented diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) through either CT or endoscopy; and -Symptoms persisting for at least 8-12 weeks despite treatment with INCS
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
N/A
Indications:
Nucala is indicated as add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by intranasal corticosteroids alone.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open12-Apr-22
Call for patient/clinician input closed06-Jun-22
Submission received11-May-22
Submission accepted